Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SARS-CoV-2 Sclamp Vaccine
NCT04495933Phase 1Completed
- Sponsor
- The University of Queensland
- Start
- Jul 2020
- Primary completion
- Apr 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of UQ-CSL V451 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by The University of Queensland. Primary endpoints: Frequency of Solicited local reactogenicity adverse events, Frequency of Solicited systemic reactogenicity adverse events and 4 more. Started Jul 2020; status: completed.
02
Drugs
UQ-CSL V451
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04495933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495933.